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Abstract
Background The non-vitamin K antagonist oral anticoagu-
lants (NOACs) overcame some limitations of vitamin K
antagonists (VKAs), and are at least as effective in stroke
prevention,with an additional decrease of intracranial bleeding
risk. The transferability of these benefits to the real world
requires tolerability (related to adverse events) and accept-
ability (drug discontinuation) profiles at least similar to VKAs.
Methods We performed a systematic review with meta-
analysis of randomized controlled trials (RCTs) evaluating
NOACs versus VKAs in patients with non-valvular atrial
fibrillation (AF). Studies were searched in April 2015
through MEDLINE, the Cochrane Collaboration’s Data-
base, Health Technology Assessment (HTA), Web of
Science, and regulatory agencies’ documents. Serious
adverse events (SAEs) as well as drug-related and patient-
related discontinuation rates were the outcomes of interest.
Random-effects meta-analysis was performed, and the
results expressed as risk ratios (RRs) and 95 % confidence
intervals (CIs). Heterogeneity was evaluated with I2 test.
Results Five RCTs evaluating four NOACs (apixaban,
dabigatran, edoxaban, and rivaroxaban) and 72,720
patients were included. Overall, NOACs were associated
with a 4 % risk reduction of SAEs (95 % CI 2–6;
I2 = 0 %). Drug-related and patient-related discontinua-
tion rates were similar between NOACs and VKAs (RR
1.03 [0.88–1.21] and RR 0.99 [0.89–1.10], respectively).
Significant heterogeneity (I2 C 75 %) was found among
studies results, which could be, at least partially, explained
by the findings of the open-label dabigatran trial.
Conclusions NOACs were associated with a small, yet
significant, risk reduction of SAEs in patients with AF.
NOACs’ drug-related and patient-related acceptability
profiles were similar to those for VKAs. The results were
heterogeneous mainly because of the increased rate of
discontinuation associated with dabigatran. Pragmatic trials
and cohort studies should be conducted to further address
these important clinical questions.
Key Points
Non-vitamin K antagonist oral anticoagulants
(NOACs) reduced significantly the risk of any
serious adverse event.
Treatment discontinuation rates were similar
between NOACs and warfarin, but there was
substantial heterogeneity, mostly related to the RE-
LY trial.
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1 Introduction
The non-vitamin K antagonist oral anticoagulants
(NOACs), such as apixaban, dabigatran, edoxaban, and
rivaroxaban were recently licensed for the prevention (after
hip or knee arthroplasty) and treatment of venous throm-
boembolism, as well as for stroke and systemic embolism
prevention in patients with non-valvular atrial fibrillation
(NVAF). While venous thromboembolism treatment or
prevention may require only temporary anticoagulant
treatment [1, 2], stroke prevention in atrial fibrillation (AF)
demands life-long treatment. As in any chronic treatment,
its effectiveness depends on tolerability and patients’
adherence to the medication.
In randomized controlled trials (RCTs), NOACs were at
least as effective as vitamin K antagonists (VKAs) in
preventing stroke and systemic embolism, and were asso-
ciated with a decreased risk of intracranial bleeding [3].
They have overcome many other limitations of VKAs,
namely the variability in dose response and the conve-
nience related to absence of frequent coagulation moni-
toring and dose adjustments.
However, these life-long potential clinical benefits only
outweigh the limitations if the adverse reactions and
medication adherence profile is at least similar to that
experienced by patients treated with VKAs. In the present
systematic review, we aimed to evaluate the tolerability
and acceptability of NOACs in patients with AF, as these
patients require long-term anticoagulation.
2 Methods
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) framework guidelines were used
for reporting guidance [4].
2.1 Search Strategy
We searched MEDLINE (Ovid), the Cochrane Collabo-
ration’s Database (Ovid), Health Technology Assess-
ment (HTA), and ISI Web of Science, all until April
2015. The search strategy was adapted from the
Cochrane Highly Sensitive Search Strategy for identi-
fying randomized trials in humans [5], and is detailed in
the supplementary electronic material (see online
resource 1). Food and Drug Administration (FDA) and
European Medicines Agency (EMA) reports were also
consulted for additional unpublished data. Reference
lists of retrieved studies and review papers were also
cross-checked.
2.2 Study Selection (Eligibility Criteria) and Data
Collection
We searched for RCTs comparing NOACs with VKAs. We
only considered for analysis phase III RCTs because we
aimed to determine the risk associated with the approved
and commonly used doses of the NOACs and to avoid bias
in risk estimation due to the impact of small size under-
powered studies on meta-analysis results [6–9]. Further-
more, phase II RCTs have small follow-up periods, which
undermines the aim of our review, which is to evaluate the
acceptability and tolerability in patients with AF (requiring
long-term anticoagulation). Studies where acetylsalicylic
acid was used as a single control arm were excluded.
Patients included in studies were required to have a
diagnosis of AF with an indication for anticoagulation.
Patients with atrial flutter were also included because the
procedures in terms of risk stratification and anticoagula-
tion should be the same as in atrial fibrillation. Studies had
to report detailed data about serious adverse events (SAEs)
and reasons for drug discontinuations. The titles and
abstracts of obtained records were screened independently
by two authors. Doubts and disagreements were solved by
a third person. Selected studies were assessed in full-text to
determine their appropriateness for inclusion. Data about
study design, patients’ characteristics, interventions, and
data of required outcomes were retrieved.
Quality of reporting was independently analyzed using
the Cochrane Collaboration’s Tool [10], which evaluates
the following items: random sequence generation method,
allocation concealment, blinding of participants and per-
sonnel, blinding of outcome assessment, incomplete out-
come data, selective reporting, description of withdrawals
and other risk of bias features deemed to be important by
investigators.
2.3 Outcome Measures
The outcomes of interest were tolerability and acceptability
of NOACs.
Tolerability was indirectly evaluated by determining the
incidence of any SAE, as reported by investigators and/or
adjudicated by committees. Whenever possible, treatment-
emergent SAEs were retrieved.
Acceptability was split into drug-related (also associated
with the tolerability profile) and patient-related treatment
discontinuation [11]. Discontinuations due to adverse
events were considered to be drug related, and discontin-
uations due to patients’ own decisions (consent withdrawal
and treatment discontinuation) were considered to be
patient related. Whenever possible, the denominator of
these outcomes was the safety population of each arm (i.e.,
patients that took the drug).
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2.4 Statistical Analysis
Statistical analyses were performed using RevMan 5.3
software (The Nordic Cochrane Centre, The Cochrane
Collaboration, 2011). Individual studies and meta-analysis
estimates were derived and presented in forest plots.
For the meta-analysis, we used the random-effects
model weighted by the inverse-variance method to estimate
pooled risk ratios (RRs) and 95 % confidence intervals
(CIs) [12]. This method was used by default independently
of the heterogeneity of the pooled analysis. RRs were
chosen to report the results because relative measures tend
to be more similar across studies than absolute estimates in
populations having different baseline characteristics and
lengths of follow-up [13]. Results were evaluated through
Z test, and these were considered significant if p\ 0.05.
Heterogeneity, defined as variation beyond chance, was
evaluated through the I2 test that measures the percentage
of total variation between studies [14]. Heterogeneity was
considered to be substantial if I2 C 50 %.
When results were statistically significant, we calculated
the number of patients needed to treat (NNT) to expect the
avoidance of one event, and the number of events avoided
per 1000 treated patients, using as baseline risk the event
rate reported in VKA-treated patients [15, 16].
Because of the expectation of inclusion of both open-
label and blinded RCTs, and considering the possible
influence of these characteristics in the analyzed outcomes,
we prespecified a subgroup analysis according to the
blinding status of included trials [17]. Despite the distinc-
tive pharmacokinetic and pharmacodynamic properties of
individual NOAC drugs, we hypothesized that these drugs
could have a class effect compared with VKAs, as shown
for some outcomes (e.g., intracranial hemorrhage). There-
fore, we did not plan an a priori subgroup analysis con-
sidering each individual NOAC drug.
Publication bias was assessed through visual inspection
of funnel plots asymmetry. Egger and Peters tests were
performed to assess objectively this risk [18, 19].
3 Results
3.1 Results of the Search and Description of Studies
After a comprehensive search for RCTs fulfilling our eli-
gibility criteria, we were able to include five phase III
RCTs evaluating four NOACs: apixaban, dabigatran,
edoxaban, and rivaroxaban (two studies with rivaroxaban)
[20–24].
Supplementary Figure 1 shows the flowchart of study
selection, with the reasons for study exclusion (see online
resource 1).
Altogether, these trials enrolled 72,720 patients with
NVAF under oral anticoagulant treatment, 59 % of them
treated with NOACs. Supplementary Table 1 details the
main characteristics of included studies.
Overall, the risk of bias was moderate according to the
qualitative Cochrane Collaboration Tool (Supplementary
Figure 2). We considered that all trials had a high risk of
selective reporting because the reporting of any adverse event
and its degree is prone to such bias. Additionally the random-
ized evaluation of long term anticoagulant therapy with dabi-
gatran etexilate (RE-LY) trial had an open-label design [21].
3.2 Tolerability and Acceptability
NOACs were associated with a small yet significant 4 % risk
reduction of SAEs in patients with NVAF (RR 0.96; 95 % CI
0.94–0.98; Fig. 1a). The results were consistent across stud-
ies, without any statistical heterogeneity (I2 = 0 %). NNT
with NOACs to expect the prevention of one SAE compared
withVKAswas 74 (95 %CI 49–148) for an average period of
1.7 years. For each 1000 patients treated withNOACs instead
ofVKAs, it is expected that 14SAEs (95 %CI7–20)wouldbe
prevented for an average period of 1.7 years.
The drug discontinuation rate due to adverse events was
similar between NOACs and VKAs (RR 1.03; 95 % CI
0.88–1.21; Fig. 1b). This analysis was remarkable for
significant statistical heterogeneity (I2 = 93 %).
Patient-related drug discontinuation was also similar
between NOACs and VKAs (RR 0.99; 95 % CI 0.89–1.10;
Fig. 1c), again showing significant statistical heterogeneity
(I2 = 75 %).
3.3 Subgroup Analysis According to Study Design
The RE-LY study (dabigatran vs. VKA) was the only open-
label trial [21]. The risk reduction of SAEs was not different
between blinded and open-label RCTs (p = 0.49; Table 1).
For both drug- and patient-related treatment discontinu-
ations, the results for dabigatran versus VKA (derived from
the open-label RE-LY trial) were significantly different
compared with the pooled results for the other NOACs
(p\ 0.0001 and p = 0.0001, respectively). Dabigatran was
associated with a significant increase of both drug- and
patient-related treatment discontinuations, while pooled
results for the other NOACs versus VKAs showed a reduc-
tion in the risk of discontinuation due to either adverse events
or patients’ own decisions (Table 1). The RE-LY trial
reported a high number of study discontinuations in dabi-
gatran-treated patients due to gastrointestinal adverse events
[21]. The level of heterogeneity in pooled estimates for
discontinuation due to drug- and patient-related causes
decreased when the RE-LY trial was removed from the
analysis (I2 = 67 % and I2 = 0 %, respectively).
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We further performed an exploratory analysis by add-
ing both drug- and patient-related treatment discontinua-
tions into a single outcome. As expected, overall NOACs
did reduce the incidence of this outcome (RR 1.00; 95 %
CI 0.88–1.14; Supplementary Figure 3), with high
heterogeneity (I2 = 95 %), mostly due to RE-LY (RR
1.25; 95 % CI 1.18–1.32). Without RE-LY, NOACs
showed a 5 % reduction of drug discontinuation risk (RR
0.95; 95 % CI 0.90–1.00; I2 = 57 %; Supplementary
Figure 3).
Fig. 1 Forest plot with meta-analysis for a SAE risk, b drug-related
treatment discontinuation risk, and c patient-related treatment
discontinuation risk. ARISTOTLE apixaban for the prevention of
stroke in subjects with atrial fibrillation, CI confidence interval,
ENGAGE-AF global study to assess the safety and effectiveness of
edoxaban vs standard practice of dosing with warfarin in patients with
atrial fibrillation, J-ROCKET rivaroxaban versus warfarin in Japanese
patients with non-valvular atrial fibrillation, NOAC non-vitamin K
antagonist oral anticoagulant, RE-LY randomized evaluation of long
term anticoagulant therapy with dabigatran etexilate, ROCKET-AF an
efficacy and safety study of rivaroxaban with warfarin for the
prevention of stroke and non-central nervous system systemic
embolism in patients with non-valvular atrial fibrillation, SAE serious
adverse event, VKA vitamin K antagonist
Table 1 Results of analysis according to study design
Trial design RCT/patients SAE Drug-related discontinuation Patient-related discontinuation
RR
[95 % CI]
I2 p value for
interaction
RR
[95 % CI]
I2 p value for
interaction
RR
[95 % CI]
I2 p value for
interaction
Double-blinded
RCTs
4/54,680 0.96
[0.94–0.98]
0 % 0.49 0.95
[0.87–1.04]
67 % \0.0001 0.95
[0.90–0.99]
0 % \0.0001
Open-label
RCT
1 (RE-LY)/
18,040
0.94
[0.88–0.99]
N/A 1.26
[1.18–1.35]
N/A 1.21
[1.08–1.36]
N/A
CI confidence interval, RCT randomized controlled trial, RR risk ratio, SAE serious adverse event, NA not available
D. Caldeira et al.
3.4 Publication Bias
The scarcity of studies makes funnel plot evaluation less
precise for risk of publication bias assessment [25].
Therefore, we only performed Egger and Peters tests, and
these were not suggestive for publication bias (p C 0.25 for
all outcomes and statistical tests).
4 Discussion
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban)
are associated with a small, yet clinical significant,
decrease in the risk of SAEs when compared with VKAs,
without differences between drugs, suggesting a drug-class
effect regarding this outcome. However, acceptability, as
evaluated through the rate of treatment discontinuation
(whether drug related or patient related) was heteroge-
neous, but not different from VKAs.
The results found among SAEs may be clinically rele-
vant as they reflect differences in the tolerability profile,
with lower risk of events with NOACs. Despite the dif-
ferent criteria attributable to the seriousness of an adverse
event, among other reasons, these are related to fatal or
life-threatening events, disabilities, or situations that
require or prolong hospitalization. Therefore, a reduction
of events associated with such outcomes may decrease the
burden associated with anticoagulated NVAF patients.
Chatterjee et al. [26] have published a review evaluating
treatment discontinuations with NOACs. They concluded
that NOACs (vs. placebo) had a higher rate of drug discon-
tinuation in patients with acute coronary syndrome. How-
ever, NOACs were not significantly different from those
with conventional drugs in terms of drug discontinuation in
NVAF and venous thromboembolism patients [26]. In our
review, different toChatterjee and colleagues,we considered
edoxaban data (ENGAGE AF-TIMI 48: Global study to
assess the safety and effectiveness of edoxaban vs standard
practice of dosing with warfarin in patients with atrial fib-
rillation) and excluded studies that could increase bias and
decrease precision, such as phase II RCTs and acetylsalicylic
acid-controlled trials. Furthermore, we concluded that
NOACs decrease the risk of SAEs, which is an important
addition to the current knowledge.
It is known that complex therapeutic regimens are
important risk factors for non-adherence [27, 28]. It is con-
ceivable that NOACs could improve patients’ acceptance of
anticoagulants due to their dose-response predictability and
not requiring frequent dose adjustments or assessment of
hemostasis parameters. Most of the trials had a double-
blinded design, and patients allocated to NOACs were also
treated with sham warfarin and INR monitoring. Therefore,
the results retrieved from those trials do not account for the
potential benefits of NOACs convenience. In terms of drug-
related discontinuation, and with the exception of dabiga-
tran, NOACs showed an acceptability overlapping that of
VKAs. In the RE-LY study, patients treated with dabigatran
had higher discontinuation rates. The knowledge about the
treatment assigned in RE-LY can, at least partially, explain
these findings because patients who know that they are being
treated with a new active drug may be more prone to dis-
continue in the setting of an adverse event. However, the
discontinuation rate in the dabigatran group due to adverse
events was also significantly higher compared with standard
anticoagulation in the double-blinded double-dummy effi-
cacy and safety of dabigatran compared to warfarin for 6
month treatment of acute symptomatic venous thromboem-
bolism (RE-COVER) trial that enrolled patients with venous
thromboembolism (hazard ratio 1.33; 95 % CI 1.01–1.76;
p = 0.05) [29]. Gastrointestinal symptoms, namely dys-
pepsia, were the main reason for premature dabigatran dis-
continuation. Other interventions (e.g., taking the drug with
meals, H2 antagonists or proton-pump inhibitors) may be
needed to mitigate these symptoms in order to improve
gastrointestinal tolerability and drug-related acceptability.
Our analysis is relevant to establishing the overall tolera-
bility profile of drugs and to generate information/signs
about any suspicious adverse events [30–32].
Concerning patient-related discontinuation (acceptabil-
ity), no differences were found between NOACs and VKAs
(RR 0.99; 95 % CI 0.89–1.10), but excluding the RE-LY
trial (open-label study) from the analysis resulted in a 5 %
significant reduction of patient-related discontinuation risk
with NOACs (RR 0.95; 95 % CI 0.90–0.99). The authors
do not have an obvious reason for the higher rate of patient-
related discontinuation among dabigatran-treated patients
(RR 1.21; 95 % CI 1.08–1.36), as well as for drug-related
discontinuation (RR 1.26; 95 % CI 1.18–1.35). It may be
hypothesized that the open-label design, by revealing to the
patients which treatment they were taking, may have led
some patients to choose to maintain their previous standard
treatment, but venous thromboembolism data (double-
blinded RCT) does not support it [29]. Other hypotheses
can be related to the reporting of a patient’s own motifs
having (elicited or not) drug-related symptoms.
This is clinically relevant because oral anticoagulant
discontinuation (or switch) is associated with a higher risk
of thromboembolic events [33].
4.1 Limitations
At outcome level, selective reporting bias was our main
concern considering the evaluation of SAEs. SAEs are
always clinically relevant, but are diverse and may not be
related to studied drugs. Some studies reported details on
SAEs, while others were more detailed on frequent adverse
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events (not SAEs). These differences did not allow com-
paring indirectly NOACs’ individual SAEs. Furthermore,
only ROCKET-AF (An efficacy and safety study of
rivaroxaban with warfarin for the prevention of stroke and
non-central nervous system systemic embolism in patients
with non-valvular atrial fibrillation) provided data about
treatment-emergent SAEs, the while other studies only
supplied information about overall adverse events.
Heterogeneity of clinical characteristics (e.g., comor-
bidities that may influence drug dosages, such as renal
dysfunction) and interventions (different NOACs, the same
NOAC at different dosages, and the possibility of different
co-medications) across the various studies should also be
considered. The statistical heterogeneity found in some
outcomes is a further limitation. Exploring the potential
sources of such heterogeneity, we found that dabigatran
showed a different acceptability profile to other NOACs.
Nevertheless, the reported NOAC results (with or without
dabigatran) were consistent in terms of direction and sig-
nificance of estimates (acceptability profile similar to that
for VKAs).
Finally, we accessed tolerability and acceptability on the
basis of data from exploratory clinical trials in a tightly
controlled environment. These outcomes are better evalu-
ated in pragmatic trials and from ‘‘real-world’’ data.
5 Conclusions
Overall, NOACs are associated with a small, yet poten-
tially clinically significant, 4 % reduction in the risk of
SAEs. NOACs’ drug-related and patient-related accept-
ability profiles were similar to those for VKAs. At this
level, NOACs did not show a clear drug-class effect. The
results were heterogeneous mainly because of the increased
rate of discontinuation in dabigatran-treated patients (pre-
dominantly associated with gastrointestinal symptoms).
These conclusions are driven from randomized data, which
is not the most powerful design to evaluate safety, tolera-
bility, and acceptability outcomes. Pragmatic trials and
large prospective cohort studies should be conducted to
address these important clinical questions.
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